GAIN THERAPEUTICS, INC (GANX) Borrowing debt
- Total debt · latest quarter (USD): Value (m); Formula and calculation Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted). Period ending 2026-06-30..
- Net cash · latest quarter: Value (m); Formula and calculation Cash and cash equivalents plus current marketable securities less interest-bearing debt; negative net cash is displayed as net debt. Period ending 2026-06-30..
- Debt / assets · latest quarter: Value (m); Formula and calculation Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted) / total assets. Period ending 2026-06-30..
Borrowing debt
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Total debt · latest quarter (USD) | (m) | Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted). Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Net cash · latest quarter | (m) | Cash and cash equivalents plus current marketable securities less interest-bearing debt; negative net cash is displayed as net debt. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Debt / assets · latest quarter | (m) | Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted) / total assets. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Borrowing debt due within one year | 123.63K USD | Long-term Debt, Current Maturities |
| Borrowing debt due after one year | 220.06K USD | Long-term Debt, Excluding Current Maturities |
| Commercial paper | (m) | |
| Cash and current securities | (m) | Cash and Cash Equivalents, at Carrying Value · Marketable Securities, Current |
| Borrowing debt | (m) | Long-term Debt, Current Maturities · Long-term Debt, Excluding Current Maturities |
| Total assets | 15.42M USD | Assets |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Total debt | Net cash / debt | Borrowing debt due within one year (USD) | Borrowing debt due after one year (USD) | Commercial paper (USD) | Cash and current securities (USD) | Total assets (USD) | Debt / assets |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | (m) | $123.63K | $220.06K | (m) | (m) | $15.42M | (m) |
| 2026-03-31 | (m) | (m) | $100.28K | $273.26K | (m) | (m) | $18.74M | (m) |
| 2025-12-31 | (m) | (m) | $100.87K | $300.08K | (m) | (m) | $22.82M | (m) |
| 2025-09-30 | (m) | (m) | $125.55K | $298.80K | (m) | (m) | $10.97M | (m) |
| 2025-06-30 | (m) | (m) | $126.11K | $325.36K | (m) | (m) | $9.83M | (m) |
| 2025-03-31 | (m) | (m) | $113.12K | $314.48K | (m) | (m) | $11.62M | (m) |
| 2024-12-31 | (m) | (m) | $110.18K | $328.33K | (m) | (m) | $12.12M | (m) |
| 2024-09-30 | (m) | (m) | $118.28K | $376.13K | (m) | (m) | $14.37M | (m) |
| 2024-06-30 | (m) | (m) | $111.05K | $375.35K | (m) | (m) | $19.20M | (m) |
| 2024-03-31 | (m) | (m) | $110.85K | $396.84K | (m) | $12.66M | $14.58M | (m) |
| 2023-12-31 | (m) | (m) | $118.80K | $449.05K | (m) | $16.79M | $18.61M | (m) |
| 2023-09-30 | (m) | (m) | $109.28K | $434.94K | (m) | $12.23M | $14.10M | (m) |
| 2023-06-30 | (m) | (m) | $111.64K | $466.64K | (m) | $16.19M | $18.26M | (m) |
| 2023-03-31 | (m) | (m) | $109.20K | $478.30K | (m) | $17.82M | $21.32M | (m) |
| 2022-12-31 | (m) | (m) | $108.14K | $495.26K | (m) | $20.14M | $24.10M | (m) |
| 2022-09-30 | (m) | (m) | $101.26K | $484.02K | (m) | $22.73M | $28.33M | (m) |
| 2022-06-30 | (m) | (m) | $83.75K | $542.26K | (m) | $24.25M | $31.89M | (m) |
| 2022-03-31 | (m) | (m) | $86.62K | $560.89K | (m) | (m) | $37.60M | (m) |
| 2021-12-31 | (m) | (m) | $103.83K | $590.47K | (m) | (m) | $38.99M | (m) |
| 2021-09-30 | (m) | (m) | $86.64K | $620.17K | (m) | (m) | $42.56M | (m) |
| 2021-06-30 | (m) | (m) | $65.47K | $646.66K | (m) | (m) | $45.35M | (m) |
| 2021-03-31 | (m) | (m) | $44.29K | $678.25K | (m) | (m) | $48.04M | (m) |
| 2020-12-31 | (m) | (m) | $22.63K | $715.66K | (m) | (m) | $9.60M | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Telomir Pharmaceuticals, Inc. (TELO) | United States | $0.084B | |
| Lexaria Bioscience Corp. (LEXX) | $0.084B | -1.92 | |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B |